Research analysts at StockNews.com began coverage on shares of Diffusion Pharmaceuticals (NASDAQ:DFFN – Get Rating) in a research report issued on Saturday. The firm set a "hold" rating on the stock.
Separately, HC Wainwright upgraded Diffusion Pharmaceuticals from a "neutral" rating to a "buy" rating and set a $9.50 price target on the stock in a report on Tuesday, August 16th.
Get Diffusion Pharmaceuticals alerts:Diffusion Pharmaceuticals Price Performance
NASDAQ:DFFN opened at $5.35 on Friday. The firm has a market capitalization of $10.91 million, a price-to-earnings ratio of -0.44 and a beta of 1.53. Diffusion Pharmaceuticals has a 1 year low of $5.10 and a 1 year high of $26.18. The business has a 50 day simple moving average of $6.47 and a 200-day simple moving average of $10.96.
Diffusion Pharmaceuticals (NASDAQ:DFFN – Get Rating) last posted its quarterly earnings data on Thursday, August 11th. The company reported ($2.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.77) by ($0.29). As a group, analysts expect that Diffusion Pharmaceuticals will post -8.43 earnings per share for the current fiscal year.Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC increased its holdings in Diffusion Pharmaceuticals by 8.3% during the 1st quarter. Renaissance Technologies LLC now owns 1,324,202 shares of the company's stock worth $331,000 after purchasing an additional 101,100 shares during the period. JPMorgan Chase & Co. purchased a new position in shares of Diffusion Pharmaceuticals in the 1st quarter valued at $106,000. Finally, Trexquant Investment LP purchased a new position in shares of Diffusion Pharmaceuticals in the 2nd quarter valued at $71,000. 10.25% of the stock is currently owned by hedge funds and other institutional investors.
About Diffusion Pharmaceuticals
(Get Rating)
Diffusion Pharmaceuticals Inc, a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc was founded in 2001 and is based in Charlottesville, Virginia.
Recommended Stories
- Get a free copy of the StockNews.com research report on Diffusion Pharmaceuticals (DFFN)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?
- Thor Industries Hammers Out A Bottom
Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.